16 patents
Utility
Methods of Treating or Reducing Risk of Transplant Rejection
14 Sep 23
The present disclosure relates to methods of treating or reducing the risk of transplant rejection or increasing a duration of time before transplant rejection occurs in a subject in need thereof (e.g., a human) by administering an antagonist that targets CD40 or CD154, such as an anti-CD40 antibody or an antigen-binding fragment thereof (e.g., a humanized anti-CD40 antibody or antigen-binding fragment thereof.
John F. PAOLINI, Muhammad M. MOHIUDDIN
Filed: 10 Jan 23
Utility
Pharmaceutical Compositions of Humanized ANTI-CD40 Antibodies
7 Sep 23
The present disclosure relates to pharmaceutical compositions of anti-CD40 antibodies, such as humanized anti-CD40 antibodies.
James Kranz
Filed: 1 Nov 22
Utility
Pharmaceutical Composition of a Humanized ANTI-CD40 Antibody
29 Jun 23
The present disclosure features a pharmaceutical formulation containing an anti-CD40 antibody, KPL-404.
James Kranz
Filed: 1 Nov 22
Utility
Treatment of Cancers with GM-CSF Antagonists
20 Oct 22
The present invention provides, among other things, a method of treating cancer comprising administering a GM-CSF antagonist to the patient in need of treatment, wherein the administration of the GM-CSF antagonist results in inhibition of an immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
Rounak Nassirpour, Joe Pirello, Eben Tessari, Luis Carvajal, Annalisa D'andrea, Francis Mussai
Filed: 3 Jun 20
Utility
Protein Compositions and Methods for Producing and Using the Same
8 Sep 22
The instant invention relates to compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, e.g., an anti-GM-CSFRα antibody or antigen binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such compositions.
Mei Jang, Dave Nichols, Baochuan Huang, Shaun Grier
Filed: 17 Dec 21
Utility
Treatment of Cancers with GM-CSF Antagonists
16 Jun 22
The present invention provides, among other things, a method of treating cancer comprising administering a GM-CSF antagonist to the patient in need of treatment, wherein the administration of the GM-CSF antagonist improves, stabilizes or reduces one or more symptoms of the cancer in the patient.
Joe Pirrello, Eben Tessari, Luis Carvajal, Annalisa D'andrea
Filed: 26 Oct 21
Utility
Treatment of cytokine release syndrome with GM-CSF antagonists
10 May 22
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation.
Joe Pirrello, John Paolini, Eben Tessari
Filed: 19 May 21
Utility
Stable Anti-OSMR Antibody Formulation
3 Mar 22
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
Filed: 8 Sep 21
Utility
Oncostatin M Receptor Antigen Binding Proteins
24 Feb 22
The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
Filed: 3 Sep 21
Utility
Stable anti-OSMR antibody formulation
12 Oct 21
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
Filed: 26 Aug 19
Utility
Treatment of Cytokine Release Syndrome with GM-CSF Antagonists
16 Sep 21
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation.
Joe Pirrello, John Paolini, Eben Tessari
Filed: 15 Mar 21
Utility
Treatment of Cytokine Release Syndrome with GM-CSF Antagonists
16 Sep 21
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation.
Joe Pirrello, John Paolini, Eben Tessari
Filed: 19 May 21
Utility
Treatment of Skin Diseases or Disorders by Delivery of Anti-osmrb Antibody
25 Feb 21
The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.
John Paolini, Rohan Gandhi, Zamaneh Mikhak
Filed: 25 Apr 19
Utility
Stable Anti-OSMR Antibody Formulation
26 Feb 20
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
Filed: 25 Aug 19
Utility
Stable anti-OSMR antibody formulation
2 Dec 19
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
Filed: 10 Apr 18
Utility
Oncostatin M Receptor Antigen Binding Proteins
27 Nov 19
The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
Filed: 6 Aug 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first